Vera Therapeutics, Inc.

NASDAQ:VERA

Biotechnology

Healthcare
$26.75 +0.27%

+$0.09 today

Market cap
$1.93B
Beta
0.95
P/E (TTM)
-6.8
EPS (TTM)
-$5.16
52W Low $19.07High $56.05

Volume 1.05M

Average 1.18M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$241.10M

FY 2025 · Annual

Investing Cash Flow

$194.29M

FY 2025 · Annual

Financing Cash Flow

$308.90M

FY 2025 · Annual

-49.1% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(32.61M)(89.06M)(95.99M)(152.15M)(299.62M)
Depreciation & Amortization176K(846K)21K105K468K
Deferred Income Tax(1.8M)0000
Stock-Based Compensation3.01M8.89M11.49M20.8M37.93M
Change in Working Capital3.51M6.75M(5.87M)2.66M22.99M
Accounts Receivables00000
Inventory00000
Accounts Payables475K10.61M(873K)(3.45M)13.91M
Other Working Capital3.04M(3.86M)(5M)6.11M9.08M
Other Non-Cash Items4M6.67M(1.84M)(6.1M)(2.88M)
Operating Cash Flow(23.71M)(67.6M)(92.18M)(134.68M)(241.1M)
Capital Expenditures0(62K)(63K)(972K)(630K)
Acquisitions (Net)796K70.49K000
Purchases of Investments0(148.49M)(224.93M)(711.99M)(310.45M)
Sales of Investments078M185.56M278.96M506.16M
Other Investing Activities(5M)(70.49K)08.97M(800K)
Investing Cash Flow(4.2M)(70.55M)(39.43M)(425.03M)194.29M
Debt Repayment4.92M19.82M24.74M023.34M
Common Stock Issued51.18M86.13M115M632.54M307.48M
Common Stock Repurchased000(13K)0
Dividends Paid00000
Other Financing Activities(2.22M)(4.01M)(6.2M)(25.85M)(21.92M)
Financing Cash Flow53.88M101.93M133.54M606.67M308.9M
Effect of Forex Changes00000
Net Change in Cash25.97M(36.22M)1.93M46.97M262.08M
Free Cash Flow(23.71M)(67.66M)(92.24M)(135.65M)(241.73M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$299.6M
+ D&A$468.0K
+ Stock-Based Comp$37.9M
+ Deferred Tax$0
+ Working Capital$23.0M
- Other Non-Cash-$2.9M
= Operating Cash Flow-$241.1M
- Capex-$630.0K
= Free Cash Flow-$241.7M

Analysis

FY2025 free cash flow is -$241.7M. FCF conversion is 80.7% of net income. Operating cash flow was -$241.1M, with capex of -$630.0K. The largest bridge item is Stock-Based Comp at $37.9M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
SC 13GSC 13G filingNov 10, 2026
10-QQuarterly reportNov 5, 2026
8-KCurrent reportNov 5, 2026
4Statement of changes in beneficial ownershipSep 17, 2026
8-KCurrent reportSep 15, 2026

Does VERA generate free cash flow?

Vera Therapeutics, Inc. (VERA) generated -$241.73M of free cash flow in fiscal 2025.

How much operating cash flow does VERA produce?

Operating cash flow was -$241.10M, before capital expenditures of $630,000.00.